Modernizing the Development of Cancer Therapeutics?

Dear Spanios Community,

What began as a vision for more reliable and efficient preclinical drug development has now grown into a movement that’s changing the future of drug discovery. Together, we’ve worked to replace outdated animal testing with next-generation, human-relevant models, and the impact has been profound. Spanios isn’t just a company; it’s a community committed to innovation in science, and to making drug development faster, cheaper, and more effective.

Now, we invite you to be a part of this exciting next chapter, not just as supporters, but as owners.

Since our founding, Spanios has pushed the boundaries of what’s possible. With COMPASS, our Custom Organoid Modelling Platform for Accurate and Speedy Solutions, we’ve created a human-relevant, translational ex-vivo system that accelerates preclinical research and provides reliable clinical outcome predictions. The results of our work have been amazing as we have seen COMPASS allow multi-arm studies at one-quarter the cost of traditional animal models and can generate data in just 4 to 12 weeks. Through the FDA Modernization Act 2.0, we can directly incorporate this data into IND filings, speeding up regulatory approvals and paving the way for greater clinical trial success.

Our journey so far has been fueled by innovation, and with your help, we’re ready to scale even further. This investment opportunity is exclusive to you, our most loyal supporters. You’ve played an integral role in getting us to this point, and now, we want you to share in the success of Spanios. Together, we can expand the reach of COMPASS, develop groundbreaking treatments, and make a lasting impact in the fight against cancer.

We are excited to offer you the chance to own a stake in Spanios, and we can’t wait to build the future with you.

With gratitude,

Bhuvanesh Dave